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To the Editor
Levels of trans-fatty acids (TFAs) in blood come from natural sources, such as milk, and 
industrial sources, such as partially hydrogenated vegetable oils. Dietary intake of TFAs 
increases low-density lipoprotein cholesterol (LDL-C) and has other adverse metabolic 
effects.1 Changing to a diet low in TFAs may lower the LDL-C level and decrease the risk 
for cardiovascular disease. To assist consumers, the Food and Drug Administration amended 
its regulations in 2003 to require that TFA content be declared on the nutrition label of foods 
and dietary supplements.2 Some community and state health departments have required 
restaurants to limit TFAs and reductions have been shown in supermarket and restaurant 
products.
The public health impact of these changes on TFA blood levels in the population is 
unknown. A preliminary study was conducted to determine plasma concentrations of TFAs 
in a subset of non-Hispanic white adults in the National Health and Nutrition Examination 
Survey (NHANES) in 2000 and 2009.
Methods
NHANES is a cross-sectional survey of the non-institutionalized civilian population of the 
United States performed annually with a complex multistage probability design, weighted to 
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be nationally representative.3 Half of the white persons aged 20 years or older who had a 
morning fasting blood sample in 2000 and 2009 were randomly selected. The protocol was 
approved by the National Center for Health Statistics Ethics Review Board and written 
informed consent was obtained.
Four TFAs (elaidic acid [C18:1n-9t], vaccenic acid [C18: 1n-7t], linoelaidic acid [C18:2n-6t,
9t], and palmitelaidic acid [C16:1n-7t]) were measured in plasma stored at −70°C, following 
previously described procedures.4,5 These are the 4 major TFAs and provide a reasonable 
representation of TFAs in blood.6 Their presence in blood cannot be used to distinguish food 
intake from natural vs industrial sources. There are no established reference ranges for TFA 
levels.
Statistical analysis was performed using SAS version 9.2 (SAS Institute Inc) and SUDAAN 
version 10.0 (Research Triangle Institute) by calculating weighted geometric means of the 
TFAs and the sum of the 4 TFAs using log-transformed data and single-year replicate 
NHANES examination weights. In addition, differences in the geometric means of the TFAs 
and the sum of the 4 TFAs from 2000 to 2009 and their 95% confidence intervals were 
calculated. Mean levels of LDL-C for this subset of NHANES participants from both years 
were determined. Because NHANES visits a limited number of locations per year, annual 
samples are nationally representative but the variance estimates for single-year data are 
higher than for multi-year data, preventing further analysis by more detailed levels of 
stratification.
Results
There were 229 participants selected from 2000 and 292 from 2009 (TABLE 1). Levels of 
TFAs were detectable in all samples. The levels of vaccenic acid decreased from 43.7 
µmol/L in 2000 to 19.4 µmol/L in 2009 (difference of 56%: 24.3 µmol/L [95% CI, 19.6-29.0 
µmol/L]). Similar changes were seen in elaidic acid, palmitelaidic acid, and linoelaidic acid. 
The weighted geometric mean of the difference for the sum of all 4 TFAs was 54.1 µmol/L 
(95% CI, 43.4–64.7 µmol/L) or 58% lower in samples from 2009 compared with samples 
from 2000 (TABLE 2). Levels of LDL-C were lower in the samples from 2009 (119.2 
mg/dL [3.09 mmol/L]) compared with the samples from 2000 (128.2 mg/dL [3.32 mmol/L]; 
Table 1).
Comment
This study is, to our knowledge, the first time information on TFAs in white adults in the US 
population has been examined. Plasma levels of TFAs were substantially lower in 2009 than 
in 2000. This may lead to a decrease in risk for cardiovascular disease in this subpopulation. 
Because this study was limited to only 2 years and only a few parameters, it does not allow 
for detailed assessments of the association with LDL-C level or other factors. These findings 
provide preliminary data on white adults only and cannot be generalized to other racial/
ethnic and age groups. Further studies to address these limitations are ongoing.
Vesper et al. Page 2
JAMA. Author manuscript; available in PMC 2018 February 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Acknowledgments
Funding/Support: The Centers for Disease Control and Prevention funded this study.
Role of the Sponsor: The Centers for Disease Control and Prevention had a role in the design and conduct of the 
study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the 
manuscript.
Additional Contributions: We thank Christina Waters, BS, Judith Heitz, BS, Tunde Meyers, MS, Antoinette 
Smith, MPH, Ashley Ribera, BS, Marcela Muresan, BS, Ashley Tippins, BS, Cindy Tse, BS, and Monir Clark, BS 
(all with the National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, 
Georgia) for their support in the laboratory measurements and Brenda Lewis, MPH (National Center for Health 
Statistics, Centers for Disease Control and Prevention, Atlanta, Georgia) for her support with specimen logistics. 
No individual received compensation for their contributions beyond their salaries.
References
1. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and 
observational evidence. Eur J Clin Nutr. 2009; 63(suppl 2):S5–S21.
2. Food and Drug Administration, HHS. Food labeling: trans fatty acids in nutrition labeling, nutrient 
content claims, and health claims: final rule. Fed Regist. 2003; 68(133):41433–41506. [PubMed: 
12856667] 
3. Centers for Disease Control and Prevention. [Accessed July 26, 2009] National Health and Nutrition 
Examination Survey. http://www.cdc.gov/nchs/nhanes.htm
4. Lagerstedt SA, Hinrichs DR, Batt SM, Magera MJ, Rinaldo P, McConnell JP. Quantitative 
determination of plasma c8-c26 total fatty acids for the biochemical diagnosis of nutritional and 
metabolic disorders. Mol Genet Metab. 2001; 73(1):38–45. [PubMed: 11350181] 
5. Mossoba, MM., Kramer, JKG. Official Methods for the Determination of Trans Fats. 2. Urbana, IL: 
AOCS Press; 2009. p. 20
6. Gebauer SK, Psota TL, Kris-Etherton PM. The diversity of health effects of individual trans fatty 
acid isomers. Lipids. 2007; 42(9):787–799. [PubMed: 17694343] 
Vesper et al. Page 3
JAMA. Author manuscript; available in PMC 2018 February 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Vesper et al. Page 4
Table 1
Characteristics of Fasting Non-Hispanic Whites Aged 20 Years or Oldera
NHANES Year of Specimen
Collection
2000
(n = 229)
2009
(n = 292)
Proportion of males, % (SE) 47.2 (2.7) 47.1 (2.7)
Weighted age, median (range), yb 45 (20–80) 46 (20–80)
Body mass index, median (interquartile range)c 26.4 (22.4–30.9) 27.5 (23.9–31.6)
Cholesterol, mean (SE), mg/dL
  Low-density lipoproteind 128.2 (2.7) 119.2 (2.3)
  High-density lipoproteine 49.6 (1.7) 55.8 (2.1)
Triglycerides, geometric mean (SE), mg/dLf 131.1 (5.2) 109.3 (5.8)
Abbreviation: NHANES, National Health and Nutrition Examination Survey.
SI conversion factors: To convert high- and low-density lipoprotein cholesterol to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply 
by 1.8.
a
Race/ethnicity was defined by participant (self-reported). All estimates are weighted using single-year replicate NHANES examination weights.
bAge has been top-coded at 80 to protect confidentiality.
cCalculated as weight in kilograms divided by height in meters squared. Due to missing data, the sample size is 289 for 2009.
d
Due to missing data, the sample size is 222 for 2000 and 280 for 2009.
e
Due to missing data, the sample size is 228 for 2000 and 291 for 2009.
f
Due to missing data, the sample size is 228 for 2000 and 290 for 2009.
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